The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) and Leiden/TransPORTEC classification used immunohistochemistry to detect the presence/absence of mismatch repair (MMR) proteins and to evaluate p53 expression, using, in both methodologies, the molecular analysis of POLE hotspot mutations. Here, POLE is linked to endometrial cancer.